Skip to main content

Market Overview

Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

Share:
Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

  • Leerink recently hosted 24 biopharmaceutical companies at a roundtable event.
  • Of the 24 companies, Leerink now rates 20 of them as Outperform.
  • Many of these 20 companies have strong potential catalysts coming relatively soon.
  • Leerink Partners recently hosted a Rare Disease Roundtable that included fireside chats with 24 biopharmaceutical companies. Following the event, analyst Joseph Schwartz released a report that included a list of 20 Outperform-rated names that attended the roundtable.

    Here’s a list of some of the potential catalysts Schwartz sees for these companies.

    Highlighted Stocks And Catalysts

  • Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR): The company is guiding conservatively for Juxtapid sales.
  • Agios Pharmaceuticals Inc (NASDAQ: AGIO): The company is seeing clinical benefit in solid tumor indications.
  • Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY): The company reports solid enrollment in APOLLO Ph. III trial and positive OLE Phase II data.
  • Related Link: Morgan Stanley Sees Drug Pricing Still An Overhang For These Names

  • Ascendis Pharma A/S (NASDAQ: ASND): The company is ramping up manufacturing ahead of Ph. III trial in growth deficiency patients.
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN): The company has a scheduled PDUFA date of December 27.
  • Cidara Therapeutics Inc (NASDAQ: CDTX): The company is executing well on CD101 development.
  • Dicerna Pharmaceuticals Inc (NASDAQ: DRNA): A decision on the fate of DCR-MYC is expected by the end of 2016.
  • Other Names

    In addition to the specific names mentioned above, Leerink also sees potential upcoming catalysts for the following Outperform-rated names in the space:

    • Auris Medical Holding AG (NASDAQ: EARS)
    • Epizyme Inc (NASDAQ: EPZM)
    • Fate Therapeutics Inc (NASDAQ: FATE)
    • Amicus Therapeutics, Inc. (NASDAQ: FOLD)
    • Insmed Incorporated (NASDAQ: INSM)
    • ProQR Therapeutics NV (NASDAQ: PRQR)
    • Uniqure NV (NASDAQ: QURE)
    • Raptor Pharmaceutical Corp. (NASDAQ: RPTP)
    • Retrophin Inc (NASDAQ: RTRX)
    • SAGE Therapeutics Inc (NASDAQ: SAGE)
    • Acceleron Pharma Inc (NASDAQ: XLRN)
    • Zafgen Inc (NASDAQ: ZFGN)
    • Zogenix, Inc. (NASDAQ: ZGNX)

    Disclosure: The author holds no position in the stocks mentioned.

    Image Credit: Public Domain

     

    Related Articles (AEGR + AGIO)

    View Comments and Join the Discussion!

    Posted-In: BiopharmaceuticalAnalyst Color Biotech Long Ideas Top Stories Analyst Ratings Trading Ideas General Best of Benzinga

    Latest Ratings

    StockFirmActionPT
    XPORaymond JamesMaintains145.0
    JBHTRaymond JamesMaintains180.0
    CAKETelsey Advisory GroupMaintains62.0
    FWRDRaymond JamesMaintains100.0
    WFCMorgan StanleyMaintains49.0
    View the Latest Analytics Ratings
    Don't Miss Any Updates!
    News Directly in Your Inbox
    Subscribe to:
    Benzinga Premarket Activity
    Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
    Market in 5 Minutes
    Everything you need to know about the market - quick & easy.
    Fintech Focus
    A daily collection of all things fintech, interesting developments and market updates.
    SPAC
    Everything you need to know about the latest SPAC news.
    Thank You

    Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com